A new solid-phase immunoradiometric assay for anti-thyroglobulin autoantibody

Area of Science:

• Immunology
• Endocrinology
• Assay Development

Background:

• Autoimmune thyroid diseases are common and often associated with autoantibodies.
• Accurate detection of anti-thyroglobulin (anti-Tg) autoantibodies is crucial for diagnosis and management.
• Existing methods may have limitations in sensitivity or quantification.

Purpose of the Study:

• To develop and validate a sensitive and quantitative immunoradiometric assay (IRMA) for anti-thyroglobulin autoantibody detection.
• To compare the performance of the new IRMA with passive hemagglutination (PH) assay.
• To assess the utility of IRMA in detecting anti-Tg in patients with autoimmune thyroid disorders.

Main Methods:

• Serum samples were tested using a newly developed IRMA involving microtiter plates coated with human thyroglobulin and detected with 125I-labeled anti-human immunoglobulin G.
• Assay sensitivity was evaluated using purified anti-Tg antibody as a standard.
• Results were compared with those obtained from passive hemagglutination (PH) assays.

Main Results:

• The IRMA detected anti-Tg in 81.2% of Hashimoto's thyroiditis/idiopathic myxedema patients, 46.4% of Graves' disease patients, 11.9% of other thyroid disorder subjects, and 4.2% of normal controls.
• The IRMA showed good correlation with the PH assay.
• The IRMA detected anti-Tg in a majority of patients with negative PH tests when using larger serum volumes, with a minimum detectable amount of 0.5 ng.

Conclusions:

• The developed IRMA is a sensitive and quantitative method for detecting anti-thyroglobulin autoantibodies.
• This assay offers improved detection capabilities, particularly for patients with low antibody levels or negative results by other methods.
• The IRMA methodology is adaptable for the quantitative measurement of other autoantibodies by using appropriate antigen-coated plates.